Zhe Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhe Jiang has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Eldad Zacksenhaus
Toronto General Research Institute-University Health Network, Toronto, ON, Canada.
6 shared publications - Yaacov Ben-David
State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang, China
4 shared publications - Dong-Yu Wang
Toronto General Research Institute-University Health Network, Toronto, ON, Canada.
3 shared publications - Philip E. D. Chung
Toronto General Research Institute, University Health Network, 101 College Street, Max Bell Research Centre, Suite 5R406, Toronto, ON M5G 1L7, Canada
3 shared publications Giovanni Ciavarra
Toronto General Research Institute—University Health Network, Toronto, Canada
2 shared publicationsHuiqin Li
Toronto General Research Institute—University Health Network, Toronto, Canada
2 shared publications
Latest Publications
- 16 April 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 135 (1) , 81-94
TLR7 signature of tumour innervation reveals two distinct pathways of triple-negative breast cancer progression
Emerging evidence indicates that tumour innervation promotes cancer progression via a non-canonical TLR7 signalling pathway. However, its impact across breast cancer subtypes, patient populations, associated molecular pathways, and oncogenic drivers remains poorly defined. We analysed TLR7 signature scores in human breast cancer across multiple datasets and evaluated their associations with prognosis, clinical outcomes, TNBC subtypes, metastasis, molecular signatures, oncogenic signalling, and pathological complete response. We demonstrate that the TLR7score signature is significantly elevated in triple-negative breast cancer (TNBC) - the most aggressive breast cancer subtype-compared with ER⁺ disease. Within TNBC, high TLR7 signalling characterises basal- and mesenchymal-like tumours relative to the luminal androgen receptor (LAR) subtype. Across multiple breast cancer cohorts, including TNBC, TLR7score alone does not uniformly predict prognosis, as both high- and low-scoring tumours are associated with reduced survival. Using sequential cut-off analysis in seven independent clinical cohorts, we show that both TLR7score-high (e.g. HR = 4.7, P = 0.01) and TLR7score-low (HR = 3.37, P = 0.038) tumours are associated with unfavourable outcomes relative to intermediate-score tumours. TLR7score-high lesions are enriched for cell proliferation, neuronal, and mast cell-related pathways, as well as RB1 and TP53 loss and elevated E2F, PI3K, MET, and MYC signalling. In contrast, TLR7score-low tumours show increased ER signalling and are enriched for T cell-associated but not neuronal pathways, delineating innervated versus non-innervated TNBC phenotypes. Moreover, TLR7score correlates with pathological complete response (pCR) in a treatment-dependent manner. Collectively, these findings suggest that TNBC progression involves both TLR7-dependent and TLR7-independent mechanisms and that TLR7score may enable patient stratification for distinct therapeutic strategies.
- 16 April 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 135 (1) , 81-94
TLR7 signature of tumour innervation reveals two distinct pathways of triple-negative breast cancer progression
Emerging evidence indicates that tumour innervation promotes cancer progression via a non-canonical TLR7 signalling pathway. However, its impact across breast cancer subtypes, patient populations, associated molecular pathways, and oncogenic drivers remains poorly defined. We analysed TLR7 signature scores in human breast cancer across multiple datasets and evaluated their associations with prognosis, clinical outcomes, TNBC subtypes, metastasis, molecular signatures, oncogenic signalling, and pathological complete response. We demonstrate that the TLR7score signature is significantly elevated in triple-negative breast cancer (TNBC) - the most aggressive breast cancer subtype-compared with ER⁺ disease. Within TNBC, high TLR7 signalling characterises basal- and mesenchymal-like tumours relative to the luminal androgen receptor (LAR) subtype. Across multiple breast cancer cohorts, including TNBC, TLR7score alone does not uniformly predict prognosis, as both high- and low-scoring tumours are associated with reduced survival. Using sequential cut-off analysis in seven independent clinical cohorts, we show that both TLR7score-high (e.g. HR = 4.7, P = 0.01) and TLR7score-low (HR = 3.37, P = 0.038) tumours are associated with unfavourable outcomes relative to intermediate-score tumours. TLR7score-high lesions are enriched for cell proliferation, neuronal, and mast cell-related pathways, as well as RB1 and TP53 loss and elevated E2F, PI3K, MET, and MYC signalling. In contrast, TLR7score-low tumours show increased ER signalling and are enriched for T cell-associated but not neuronal pathways, delineating innervated versus non-innervated TNBC phenotypes. Moreover, TLR7score correlates with pathological complete response (pCR) in a treatment-dependent manner. Collectively, these findings suggest that TNBC progression involves both TLR7-dependent and TLR7-independent mechanisms and that TLR7score may enable patient stratification for distinct therapeutic strategies.
- 10 July 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (30) , 2662-2674
The tumor suppressor pRb and its relative p130 are required to maintain murine adult skeletal muscle homeostasis
The retinoblastoma tumor suppressor pRB is required for skeletal myogenesis but its role in maintenance of post-mitotic skeletal muscle and the contribution, if any, of its relatives, p107 and p130, are largely unknown. Here, we show that targeted deletion of murine Rb in proliferating myoblasts during myogenesis, using a Pax7-Cre deleter line, leads to muscle fiber degeneration, short myotubes with elongated, large nuclei, reduced late muscle marker expression, and fetal death. These defects are recapitulated in primary myoblasts derived from Pax7-Cre:Rbf/f mice, can be ameliorated by inhibition of autophagy in vitro, and are exacerbated in Pax7-Cre:Rbf/f:p107–/– but not Pax7-Cre:Rbf/f:p130–/– double mutant fetuses. In contrast, deletion of Rb on a wildtype or p107–/– background in post-mitotic muscle, via an Mlc1f-Cre deleter line, has no apparent impact on skeletal muscle homeostasis. However, approximately 10% of Mlc1f-Cre:Rbf/f:p130–/– mice, with combined deletion of Rb and p130, exhibit reduced size, wobbly, waddling gait, along with muscle degeneration and dramatic reduction in skeletal muscle mass. The remaining Mlc1f-Cre:Rbf/f:p130–/– mice had near normal posture and muscle mass, but certain muscle areas show extensive central nuclei, while whole muscles express elevated levels of Pax7 and autophagic markers, suggestive of excessive muscle degeneration and regeneration. These mice also display muscle fiber type redistribution accompanied by reduced PGC-1α expression. Thus, continuous pRB and p130 expression is required to maintain skeletal muscle homeostasis and prevent adult muscle degeneration. Moreover, genetic modifiers—yet to be defined—affect the balance between muscle atrophy and regeneration.
- 10 July 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (30) , 2662-2674
The tumor suppressor pRb and its relative p130 are required to maintain murine adult skeletal muscle homeostasis
The retinoblastoma tumor suppressor pRB is required for skeletal myogenesis but its role in maintenance of post-mitotic skeletal muscle and the contribution, if any, of its relatives, p107 and p130, are largely unknown. Here, we show that targeted deletion of murine Rb in proliferating myoblasts during myogenesis, using a Pax7-Cre deleter line, leads to muscle fiber degeneration, short myotubes with elongated, large nuclei, reduced late muscle marker expression, and fetal death. These defects are recapitulated in primary myoblasts derived from Pax7-Cre:Rbf/f mice, can be ameliorated by inhibition of autophagy in vitro, and are exacerbated in Pax7-Cre:Rbf/f:p107–/– but not Pax7-Cre:Rbf/f:p130–/– double mutant fetuses. In contrast, deletion of Rb on a wildtype or p107–/– background in post-mitotic muscle, via an Mlc1f-Cre deleter line, has no apparent impact on skeletal muscle homeostasis. However, approximately 10% of Mlc1f-Cre:Rbf/f:p130–/– mice, with combined deletion of Rb and p130, exhibit reduced size, wobbly, waddling gait, along with muscle degeneration and dramatic reduction in skeletal muscle mass. The remaining Mlc1f-Cre:Rbf/f:p130–/– mice had near normal posture and muscle mass, but certain muscle areas show extensive central nuclei, while whole muscles express elevated levels of Pax7 and autophagic markers, suggestive of excessive muscle degeneration and regeneration. These mice also display muscle fiber type redistribution accompanied by reduced PGC-1α expression. Thus, continuous pRB and p130 expression is required to maintain skeletal muscle homeostasis and prevent adult muscle degeneration. Moreover, genetic modifiers—yet to be defined—affect the balance between muscle atrophy and regeneration.
- Open Access
Recent Advances in Pineoblastoma Research: Molecular Classification, Modelling and Targetable Vulnerabilities
Pineoblastoma (PB) is a rare yet lethal pediatric brain cancer of the pineal gland, a small endocrine organ that secretes melatonin to regulate the circadian rhythm. For PB patients ≤5 years of age, the overall survival rate is approximately 15%; metastatic PB is incurable. Standard treatment, including surgical resection, radiation, and systemic chemotherapy, improves survival but compromises neurocognitive function. A better understanding of the disease and the generation of preclinical models may enable re-evaluation of previous clinical trials, development of precision therapeutic strategies and improve patient outcome. Over the past 5 years, PB has been recognized to include several major subtypes driven by (i) loss of microRNA processing factors DICER and DROSHA characterized by a relatively good prognosis; (ii) loss of the retinoblastoma tumor suppressor RB1; and (iii) amplification or induction of the cMYC protooncogene, with the latter two subtypes exhibiting exceedingly poor prognosis. Recently, mouse models for the major PB subtypes (RB1-, DICER1- and DROSHA-) except MYC- have been established. This progress, including better understanding of the disease, cell of origin, tumor progression, role of autophagy, and targetable vulnerabilities, holds promise for novel therapeutic strategies to combat each subtype of this lethal childhood malignancy.
Open AccessRecent Advances in Pineoblastoma Research: Molecular Classification, Modelling and Targetable Vulnerabilities
Pineoblastoma (PB) is a rare yet lethal pediatric brain cancer of the pineal gland, a small endocrine organ that secretes melatonin to regulate the circadian rhythm. For PB patients ≤5 years of age, the overall survival rate is approximately 15%; metastatic PB is incurable. Standard treatment, including surgical resection, radiation, and systemic chemotherapy, improves survival but compromises neurocognitive function. A better understanding of the disease and the generation of preclinical models may enable re-evaluation of previous clinical trials, development of precision therapeutic strategies and improve patient outcome. Over the past 5 years, PB has been recognized to include several major subtypes driven by (i) loss of microRNA processing factors DICER and DROSHA characterized by a relatively good prognosis; (ii) loss of the retinoblastoma tumor suppressor RB1; and (iii) amplification or induction of the cMYC protooncogene, with the latter two subtypes exhibiting exceedingly poor prognosis. Recently, mouse models for the major PB subtypes (RB1-, DICER1- and DROSHA-) except MYC- have been established. This progress, including better understanding of the disease, cell of origin, tumor progression, role of autophagy, and targetable vulnerabilities, holds promise for novel therapeutic strategies to combat each subtype of this lethal childhood malignancy.
- Open Access
Thinking (Metastasis) outside the (Primary Tumor) Box
The metastasis of tumor cells into vital organs is a major cause of death from diverse types of malignancies
Open AccessThinking (Metastasis) outside the (Primary Tumor) Box
The metastasis of tumor cells into vital organs is a major cause of death from diverse types of malignancies
- Open Access
- 13 January 2022
- Published by Springer Nature in The EMBO Journal
- Vol. 41 (4) , e106825
Hypophosphorylated pRb knock‐in mice exhibit hallmarks of aging and vitamin C‐preventable diabetes
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- 13 January 2022
- Published by Springer Nature in The EMBO Journal
- Vol. 41 (4) , e106825
Open AccessHypophosphorylated pRb knock‐in mice exhibit hallmarks of aging and vitamin C‐preventable diabetes
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- 21 January 2015
- Published by Taylor & Francis in Natural Product Research
- Vol. 29 (19) , 1839-1844
Two new diarylheptanoids isolated from the roots ofJuglans mandshurica
Two new diarylheptanoids, ( - )-threo-3',4″-epoxy-1-(4-hydroxyphenyl)-7-(3-methoxyphenyl)heptan-2,3-diol (1) and (1α,3β,5α,6α)-1,5-epoxy-3,6-dihydroxy-1,7-bis(3-methoxy-4-hydroxy-phenyl)-heptane (2), along with one known diarylheptanoid, rhoiptelol B (3), were isolated from the roots of Juglans mandshurica. The structures of compounds 1 and 2 were identified based on HR-ESI-MS, 1D and 2D NMR including (1)H-(1)H COSY, HMQC, HMBC and NOESY spectroscopic methods.
- 21 January 2015
- Published by Taylor & Francis in Natural Product Research
- Vol. 29 (19) , 1839-1844
Two new diarylheptanoids isolated from the roots ofJuglans mandshurica
Two new diarylheptanoids, ( - )-threo-3',4″-epoxy-1-(4-hydroxyphenyl)-7-(3-methoxyphenyl)heptan-2,3-diol (1) and (1α,3β,5α,6α)-1,5-epoxy-3,6-dihydroxy-1,7-bis(3-methoxy-4-hydroxy-phenyl)-heptane (2), along with one known diarylheptanoid, rhoiptelol B (3), were isolated from the roots of Juglans mandshurica. The structures of compounds 1 and 2 were identified based on HR-ESI-MS, 1D and 2D NMR including (1)H-(1)H COSY, HMQC, HMBC and NOESY spectroscopic methods.
- 1 December 2004
- Published by Elsevier in Gene Expression Patterns
- Vol. 5 (2) , 245-251
High expression during neurogenesis but not mammogenesis of a murine homologue of the Deleted in Breast Cancer2/Rhobtb2 tumor suppressor
- 1 December 2004
- Published by Elsevier in Gene Expression Patterns
- Vol. 5 (2) , 245-251
High expression during neurogenesis but not mammogenesis of a murine homologue of the Deleted in Breast Cancer2/Rhobtb2 tumor suppressor